Alkhelaiwy Lara, Fatani Jumana A, Alhamoud Ismaeil, Chaballout Ahmed
General Surgery, Specialized Medical Center, Riyadh, SAU.
General Surgery/Kidney Transplant and Vascular Surgery, Specialized Medical Center, Riyadh, SAU.
Cureus. 2024 Feb 10;16(2):e53955. doi: 10.7759/cureus.53955. eCollection 2024 Feb.
Post-vaccination immune thrombocytopenia (ITP) is a rare but recognized adverse event believed to result from an autoimmune reaction triggered by the vaccine. This case report presents the fourth documented instance of severe ITP requiring splenectomy following the administration of a COVID-19 vaccine. The patient, a 54-year-old previously healthy female with no familial history of autoimmune or hematological disorders, developed ITP two weeks after the first dose of the COVID-19 vaccine. While most ITP cases associated with COVID-19 vaccines manifested after the second dose, this unique case demonstrated symptoms following the initial vaccination. Initially responsive to first-line management, the patient experienced a relapse upon receiving the second dose from a different vaccine manufacturer. Despite exhaustive medical interventions, the refractory nature of the condition persisted, ultimately mandating splenectomy for the achievement of complete remission. This case underscores the potential for serious, refractory ITP with the second dose of a COVID-19 vaccine, particularly in patients who initially developed ITP after the first dose, even if they had seemingly achieved complete remission. These findings emphasize the importance of vigilant monitoring and individualized treatment strategies in such cases, contributing valuable insights to the growing body of knowledge surrounding vaccine-induced ITP.
接种疫苗后免疫性血小板减少症(ITP)是一种罕见但已被认可的不良事件,被认为是由疫苗引发的自身免疫反应所致。本病例报告介绍了第四例有记录的在接种新冠疫苗后出现严重ITP并需要进行脾切除术的病例。该患者为一名54岁的既往健康女性,无自身免疫或血液系统疾病家族史,在接种第一剂新冠疫苗两周后患上ITP。虽然大多数与新冠疫苗相关的ITP病例在接种第二剂后出现症状,但该独特病例在初次接种后即出现症状。患者最初对一线治疗有反应,但在接种来自不同疫苗制造商的第二剂疫苗后病情复发。尽管进行了全面的医学干预,病情的难治性仍然存在,最终不得不进行脾切除术以实现完全缓解。本病例强调了接种第二剂新冠疫苗后出现严重难治性ITP的可能性,特别是对于那些在接种第一剂后最初出现ITP的患者,即使他们似乎已实现完全缓解。这些发现强调了在此类病例中进行密切监测和个体化治疗策略的重要性,为围绕疫苗诱导的ITP的不断增长的知识体系提供了有价值的见解。